Anticitrulin antibody and the extra-articular manifestations in rheumatoid arthritis;Anticuerpo anticitrulina y manifestaciones extra articulares en artritis reumatoidea

Medicina (Argentina)

Volumn 73, Issue 1, 2013, Pages 21-25

  Salinas, María Jezabel Haye ^a   Retamozo, Soledad ^a   Vetorazzi, Lorena ^a   Peano, Natalia ^a   Cuiza, Patricia Ericka Díaz ^a   Menescardi, María Sol Castaños ^a   Miretti, Evangelina María ^a   Encinas, Laura Mariela ^a   Álvarez, Ana Cecilia ^a   Saurit, Verónica ^a   Alvarellos, Alejandro ^a   Caeiro, Francisco ^a  

^a HOSPITAL PRIVADO   (Argentina)

Author keywords

Citrullinated peptide; Extra articular manifestations; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; PATHOGENESIS; RHEUMATOID ARTHRITIS; SMOKING HABIT; SUBCUTANEOUS NODULE; XEROPHTHALMIA; XEROSTOMIA;

AGED; ARTHRITIS, RHEUMATOID; CITRULLINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PULMONARY FIBROSIS; RHEUMATOID FACTOR; RISK FACTORS; SMOKING; XEROPHTHALMIA; XEROSTOMIA;

EID: 84877879607     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722-7.
2. Cimmino MA, Salvarini C, Macchioni P, et al. Extra-articular manifestations in 587 italian patients with rheumatoid arthritis. Rheumatol Int 2000; 19: 213-7.
3. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54-8.
4. Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology 1999; 38: 668-74.
5. Turesson C, Jacobsson LTH, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 59-64.
6. Melsom RD, Horsfall AC, Schrieber L, Charles P, Maini RN. Anti-C1q affinity isolated circulating immune complexes correlate with extra-articular rheumatoid disease. Rheumatol Int 1986; 6: 227-31.
7. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63.
8. Yamada R, Suzuki A, Chang X, Yamamoto K. Peptidylarginine deiminase type 4: identification of a rheumatoid arthritis-susceptible gene. Trends Mol Med 2003; 9: 503-8.
9. Nielen MMJ, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis. Arthritis Rheum 2004; 50: 380-6.
10. Forslind K, Ahlmen M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 1090-5.
11. Bukhari M, Thomson W, Naseem H, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis. Results from the Norfolk Arthritis Register. Arthritis & Rheumatism 2007; 56: 2929-35.
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 1988; 31: 315-24.
13. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
14. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas L. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008; 27: 511-13.
15. De Rycke L, Peene I, Hoffman IEA, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004; 63: 1587-93.
16. Goeldner I, Skare TL, de Messias Reason IT, Nisihara RM, Silva M, da Rosa Utiyama SR. Association of anticyclic citrullinated peptide antibodies with extra-articular manifestations, gender and tabagism in rheumatoid arthritis patients from southern Brazil. Clin Rheumatol 2011; 30: 975-80.
17. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008; 67: 1488-92.
18. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLADR (shared epitope)-restricted immune reactions to antigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
19. Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. The Journal of Rheumatology 2008; 34: 995-1001.
20. Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos A. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?. Clin Exp Rheumatol 2005; 23: 861-6.